GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cybin Inc (FRA:R7E1) » Definitions » Gross-Profit-to-Asset %

Cybin (FRA:R7E1) Gross-Profit-to-Asset % : 0.00% (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Cybin Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Cybin's annualized Gross Profit for the quarter that ended in Dec. 2023 was €0.00 Mil. Cybin's average Total Assets over the quarter that ended in Dec. 2023 was €64.29 Mil. Therefore, Cybin's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 0.00%.


Cybin Gross-Profit-to-Asset % Historical Data

The historical data trend for Cybin's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cybin Gross-Profit-to-Asset % Chart

Cybin Annual Data
Trend Mar20 Mar21 Mar22 Mar23
Gross-Profit-to-Asset %
- 0.43 - -

Cybin Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Gross-Profit-to-Asset % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Cybin's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Cybin's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cybin's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cybin's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Cybin's Gross-Profit-to-Asset % falls into.



Cybin Gross-Profit-to-Asset % Calculation

Cybin's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Mar. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (A: Mar. 2023 )/( (Total Assets (A: Mar. 2022 )+Total Assets (A: Mar. 2023 ))/ count )
=0/( (60.292+36.79)/ 2 )
=0/48.541
=0.00 %

Cybin's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %=Gross Profit (Q: Dec. 2023 )/( (Total Assets (Q: Sep. 2023 )+Total Assets (Q: Dec. 2023 ))/ count )
=0/( (39.906+88.668)/ 2 )
=0/64.287
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.


Cybin Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Cybin's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cybin (FRA:R7E1) Business Description

Industry
Traded in Other Exchanges
Address
100 King Street West, Suite 5600, Toronto, ON, CAN, M5X 1C9
Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The company is focused on advancing psychedelic-based therapies, delivery mechanisms, novel compounds and protocols as potential treatments for various psychiatric and neurological conditions.

Cybin (FRA:R7E1) Headlines

No Headlines